



ASX Announcement

For immediate release

11 May 2022

Update Regarding Vifor Pharma Acquisition

CSL Limited (ASX: CSL; USOTC:CSLLY) has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. CSL now expects the regulatory approval process to take a few more months.

CSL remains confident of completing its acquisition of Vifor Pharma AG and looks forward to expanding its presence in the rapidly growing nephrology market, as well as leveraging the companies' combined expertise to continue to deliver innovative solutions to rare and serious illness.

ENDS

Authorised by
Fiona Mead
Company Secretary

FURTHER INFORMATION

For further information, please contact:

Investors:

Bernard Ronchi
Associate Director, Investor Relations
CSL Limited
Telephone: +613 9389 3470
Email: bernard.ronchi@csl.com.au

Media:

Jimmy Baker
Communications, Asia Pacific
CSL Limited
Mobile +61 450 909 211
Email: jimmy.baker@csl.com.au